Plain-English translation of NCT06951997 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called combined with three other medications—chemotherapy drugs and a treatment that affects how cancer cells behave—as a first-line treatment for advanced pancreatic cancer that has spread to other parts of the body. Researchers want to see if this combination works better and is safe for patients who have never had cancer treatment before. The study will include 33 patients at a single hospital in China.
Advanced pancreatic cancer is very difficult to treat, and current standard treatments have limited effectiveness. This trial explores whether adding this new immunotherapy medication to existing chemotherapy approaches might help more patients live longer and have better outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive intravenous infusions of the medication combination every 3 weeks. Each dose includes , two chemotherapy drugs ( and ), and an oral medication called taken twice weekly. You would have regular blood tests and imaging scans to monitor how well the treatment is working and watch for any side effects. The study takes place at a single cancer hospital, and you would need to be able to commit to the treatment schedule and follow-up visits.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~33 participants
Started
March 2025
Primary completion
May 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rui Liu, MD
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.